TLR2激动通过重编程白血病干细胞抑制髓系白血病发生
本研究在高危急性髓系白血病(AML)模型中探讨Toll样家族受体(TLR)配体的作用,发现TLR2配体具有区别于其他TLR的抗白血病效应。TLR2信号在单细胞水平诱导细胞类型依赖的分化转录反应,协调增殖、分化、细胞死亡和免疫细胞功能激活,是唯一能通过重编程白血病干细胞(LSC)、升高MHC II类表面表达并损害自我更新来延长AML小鼠生存的TLR激动剂。TLR2与MHCII基因共表达与AML患者更好的总生存相关,与小鼠中TLR2信号激活的观察一致。
要点
- TLR2配体是唯一能延长AML小鼠生存的TLR激动剂,通过重编程LSC实现。
- TLR2信号升高MHC II类表面表达并损害LSC自我更新。
- TLR2与MHCII基因共表达与AML患者更好的总生存相关。
核心结论
- TLR2信号功能性拮抗白血病发生,TLR2激动在AML中具有重要作用。
研究设计与样本
- 在高危AML模型中使用针对Toll样家族受体(TLR)的配体进行研究,并在单细胞水平分析转录反应。
主要发现
- TLR2配体在AML细胞中广泛诱导炎症基因表达,单细胞水平呈现细胞类型依赖的分化转录反应,协调增殖、分化、细胞死亡和免疫细胞功能激活。
- TLR2配体是唯一能延长AML小鼠生存的TLR激动剂,通过LSC重编程升高MHC II类表面表达并最终损害自我更新。
- TLR2与MHCII基因共表达与AML患者更好的总生存相关,与小鼠中TLR2信号激活的观察一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The consequences of activated innate immune signaling in acute myeloid leukemia (AML) is not well understood. Using ligands directed at the toll-like family receptors (TLR) in models of high-risk AML, we uncover that TLR2 ligands exert unique antileukemic effects that are distinct from other TLRs. Although TLR2 signaling broadly induces inflammatory gene expression in AML cells, at the single-cell level, cell-type-dependent, divergent transcriptional responses coordinate cellular outputs of proliferation, differentiation, cell death, and activation of immune cell function. TLR2 ligands were the only TLR agonists capable of extending survival of AML-bearing mice through leukemia stem cell (LSC) reprogramming that elevated major histocompatibility complex (MHC) class II surface expression and ultimately impaired self-renewal. We find that the coexpression of TLR2 and MHCII genes is associated with better overall survival in patients with AML, which is consistent with our observations of activated TLR2 signaling in mice. These data reveal functional TLR2 signaling critically antagonizes leukemogenesis and emphasizes a role for TLR2 agonism in AML.
引用
- Lawler ME, Romer-Seibert JS, Bowman MS, et al. TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells. Blood Adv. 2025. PMID: 40833891. doi:10.1182/bloodadvances.2025017018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。